Polycythemia vera

What is Polycythemia vera?

Polycythemia vera (PV) is a rare blood cancer that causes the bone marrow to produce too many red blood cells, leading to thickened blood and increased risk of blood clots. This chronic myeloproliferative neoplasm primarily affects adults, with most diagnoses occurring between ages 50-75. With a prevalence of approximately 44-57 cases per 100,000 people, PV is considered a rare disease that requires specialized hematologic care. While incurable, modern treatments can effectively manage symptoms and help patients live near-normal lifespans.

Key statistics

Symptoms

Common symptoms: Fatigue, headaches, dizziness, itching after bathing (aquagenic pruritus), facial flushing, enlarged spleen, burning sensation in hands and feet.

Early symptoms often include persistent fatigue and headaches due to thickened blood flow. Many patients experience intense itching, particularly after warm baths or showers, which can be one of the most distressing symptoms. As the condition progresses, patients may notice facial redness, especially after sun exposure or physical activity. The spleen typically enlarges as it works overtime to process excess blood cells, sometimes causing abdominal discomfort or early satiety. Vision problems, including blurred vision or blind spots, can occur due to changes in blood flow to the eyes. Some patients develop erythromelalgia, a burning pain in the hands and feet accompanied by redness and warmth. Night sweats, unexplained weight loss, and easy bruising or bleeding may also develop. Without treatment, more serious symptoms can emerge, including severe blood clots that may cause stroke, heart attack, or pulmonary embolism.

Causes and risk factors

Polycythemia vera is caused by an acquired genetic mutation, most commonly the JAK2 V617F mutation found in approximately 95% of patients. This mutation occurs in hematopoietic stem cells and leads to overproduction of red blood cells, white blood cells, and platelets. Unlike inherited genetic disorders, PV develops during a person’s lifetime and is not passed down from parents. The exact trigger for this mutation remains unknown, though some research suggests potential links to radiation exposure or certain chemicals. Advanced age is the primary risk factor, with most cases occurring after age 50. Men have a slightly higher risk than women. Jewish ancestry, particularly Ashkenazi Jewish heritage, appears to confer increased susceptibility. Previous radiation therapy or chemotherapy may slightly increase risk, though most patients have no identifiable predisposing factors.

Submit Your Paper

Prevention

There is no known way to prevent polycythemia vera since it results from acquired genetic mutations that occur randomly during a person’s lifetime. Unlike hereditary conditions, PV is not inherited from parents, so genetic counseling for family members is typically not necessary. However, regular health screenings that include complete blood counts can help detect elevated red blood cell levels early, potentially leading to earlier diagnosis and treatment. Individuals with unexplained persistent fatigue, headaches, or the characteristic itching after bathing should seek medical evaluation. While family history of PV is rare, family members may benefit from awareness of symptoms given the slight possibility of shared genetic predispositions.

Complications

Without treatment, polycythemia vera can lead to life-threatening complications. Blood clots represent the most serious risk, potentially causing stroke, heart attack, deep vein thrombosis, or pulmonary embolism. The thickened blood strains the cardiovascular system, increasing risks of high blood pressure and heart failure. Severe splenomegaly can cause abdominal pain and interfere with eating. Bleeding complications may paradoxically occur despite increased blood cell counts, due to platelet dysfunction. Over time, approximately 10-15% of patients may develop myelofibrosis, where scar tissue replaces normal bone marrow, leading to severe anemia and constitutional symptoms. A small percentage (2-5%) may progress to acute leukemia, particularly after many years of disease or certain treatments. Gout can develop due to increased cell turnover and elevated uric acid levels. Early diagnosis and appropriate treatment significantly reduce these complication risks.

Diagnosis

Diagnosis typically begins with blood tests showing elevated hemoglobin, hematocrit, and often elevated white blood cells and platelets. The World Health Organization criteria require hemoglobin levels above 16.5 g/dL in men or 16.0 g/dL in women, or elevated red blood cell mass. Genetic testing for the JAK2 V617F mutation is essential, as it’s present in 95% of PV patients. Bone marrow biopsy may be performed to assess cellular morphology and exclude other conditions, showing hypercellularity with increased production of all blood cell lines. Serum erythropoietin levels are typically low or normal, helping distinguish PV from secondary causes of elevated red blood cells. Additional tests may include vitamin B12 levels (often elevated), lactate dehydrogenase (frequently increased), and uric acid levels. Abdominal ultrasound or CT scan can assess spleen size. The diagnostic journey often begins when routine blood work reveals unexpected abnormalities, though some patients are diagnosed after investigating symptoms like persistent itching or fatigue that initially seemed unrelated to blood disorders.

Treatment

Treatment aims to reduce blood thickness, prevent clots, and manage symptoms. Phlebotomy (therapeutic blood removal) is often the first-line treatment, performed regularly to maintain target hematocrit levels below 45%. Low-dose aspirin is typically prescribed to reduce clotting risk unless contraindicated. For patients requiring additional therapy, hydroxyurea is commonly used as a cytoreductive agent to suppress blood cell production. Ruxolitinib, a JAK2 inhibitor, is approved for patients who cannot tolerate or are resistant to hydroxyurea, and is particularly effective for reducing spleen size and constitutional symptoms. Ropeginterferon alfa-2b represents a newer treatment option, offering convenient dosing every two weeks and potentially disease-modifying effects. Allopurinol may be prescribed to prevent gout. Antihistamines can help manage itching, though this symptom often improves with disease control. Treatment plans are individualized based on patient age, symptoms, risk factors, and treatment tolerance.

Prognosis

With appropriate treatment, many patients with polycythemia vera can expect near-normal lifespans and good quality of life. The 15-year survival rate is approximately 80% with modern management. Prognosis depends significantly on age at diagnosis, with younger patients generally having better long-term outcomes. Risk stratification helps guide treatment intensity: patients over 60 or with previous thrombotic events are considered high-risk and require more aggressive management. Without treatment, median survival is significantly reduced due to thrombotic and hemorrhagic complications. The main factors affecting prognosis include development of thrombotic events, progression to myelofibrosis or acute leukemia, and individual response to treatment. Regular monitoring and adherence to treatment recommendations are crucial for maintaining optimal outcomes. Many patients can continue working and pursuing normal activities with appropriate medical management.

Quality of life

Living with polycythemia vera requires ongoing medical management but need not severely limit daily activities. Regular exercise is generally encouraged and can help improve circulation and energy levels, though patients should stay well-hydrated and avoid overheating. Dietary modifications may include reducing iron-rich foods to help slow red blood cell production, though specific restrictions vary by individual. Many patients find that cool showers help minimize the characteristic post-bathing itching. Sun protection is important as facial flushing can be exacerbated by UV exposure. Stress management techniques may help with symptom control and overall well-being. Patients should maintain regular sleep schedules and address fatigue through pacing activities. Mental health support can be valuable, as living with a chronic blood cancer can cause anxiety or depression. Most patients can continue working, though some may need accommodations for medical appointments or fatigue. Travel is generally possible with proper planning and ensuring access to medical care. Open communication with healthcare providers about symptom changes is essential for optimizing quality of life.

Pregnancy and fertility

Polycythemia vera can complicate pregnancy, requiring specialized management by both hematologists and high-risk obstetricians. The condition increases risks of blood clots, pregnancy loss, preeclampsia, and growth restriction. Fertility is not typically directly affected by PV itself, though some treatments may impact reproductive function. Women planning pregnancy should optimize disease control beforehand and may need to switch medications, as hydroxyurea is contraindicated during pregnancy. Interferon-based treatments may be safer options during pregnancy. Increased monitoring throughout pregnancy is essential, with more frequent blood counts and fetal surveillance. Low-dose aspirin is often recommended to reduce clotting risks. Delivery planning should account for bleeding and clotting risks. Men with PV should discuss fertility preservation if considering treatments that might affect sperm production. Genetic counseling is generally not necessary since PV is an acquired condition, not inherited.

Children

Polycythemia vera is extremely rare in children, with most cases occurring in adults over 50. When PV does occur in pediatric patients, it often presents differently than in adults and may require modified treatment approaches. Children may be more likely to have larger spleens and constitutional symptoms. Treatment decisions must balance disease control with potential effects on growth and development. Hydroxyurea is sometimes used in children but requires careful monitoring. Phlebotomy can be more challenging in smaller patients. Pediatric patients need specialized care from hematologists experienced in childhood blood disorders. Long-term follow-up is crucial given the decades of life ahead and potential for disease evolution.

When to see a doctor

Seek immediate medical attention for symptoms suggesting blood clots: sudden severe headache, vision changes, chest pain, shortness of breath, leg swelling or pain, or signs of stroke. Urgent evaluation is needed for severe abdominal pain (possible splenic complications), significant bleeding, or concerning neurological symptoms. Routine medical care should be sought for persistent fatigue, unexplained itching after bathing, frequent headaches, facial redness, or abnormal blood test results. Patients with diagnosed PV should maintain regular hematology follow-up and contact their healthcare team for symptom changes, medication side effects, or concerns about disease progression. Annual monitoring typically includes blood counts, physical examination, and assessment for complications.

Regional context

Specific prevalence data for polycythemia vera in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries is limited. The condition appears to occur at similar rates across different populations globally, though some studies suggest slightly higher incidence in individuals of Jewish ancestry. Regional healthcare systems may vary in access to specialized hematologic care and newer treatments like ruxolitinib or ropeginterferon alfa-2b. We invite healthcare professionals and researchers from the Caucasus and Eastern Mediterranean regions to contribute regional data and experiences with PV management to Global Medical Journal to better understand local prevalence patterns and treatment accessibility.

Research and clinical trials

Current research focuses on developing more targeted therapies, understanding disease mechanisms, and improving quality of life. Studies are investigating new JAK inhibitors, combination therapies, and potential curative approaches including stem cell transplantation in select cases. Research into interferon’s potential disease-modifying effects continues, with studies examining whether it can reverse bone marrow fibrosis or reduce mutation burden. Clinical trials are exploring novel agents targeting different pathways involved in PV pathogenesis. Biomarker research aims to better predict disease progression and treatment response. Patients interested in clinical trials can search ClinicalTrials.gov for current studies. The MPN Research Foundation actively supports research initiatives and provides information about ongoing trials. Recent breakthroughs include better understanding of driver mutations beyond JAK2 and development of more tolerable interferon formulations.

Frequently asked questions

Is polycythemia vera inherited?

No, polycythemia vera is an acquired condition caused by genetic mutations that develop during a person’s lifetime. It is not passed down from parents to children, so family members are not at increased risk of inheriting the condition.

Can polycythemia vera be cured?

Currently, there is no cure for polycythemia vera, but it can be effectively managed with treatment. Many patients live near-normal lifespans with good quality of life through proper medical management including phlebotomy and medications when needed.

Why do I itch after bathing?

Aquagenic pruritus (itching after water contact) affects up to 70% of PV patients and results from release of histamine and other substances when blood cells interact with temperature changes. This symptom often improves with disease control and can be managed with antihistamines and cooler water temperatures.

How often will I need blood removal (phlebotomy)?

Phlebotomy frequency varies by individual but typically ranges from weekly initially to every few months once target blood levels are achieved. The goal is maintaining hematocrit below 45% while monitoring symptoms and blood counts regularly.

Will I develop leukemia?

The risk of progression to acute leukemia is relatively low, occurring in approximately 2-5% of PV patients over many years. This risk may be slightly higher with certain older treatments, but modern management approaches aim to minimize this possibility while effectively controlling the disease.

Support and resources

MPN Research Foundation – Comprehensive resources, research updates, and patient support for myeloproliferative neoplasms including PV.
Website: mpnresearchfoundation.org

National Organization for Rare Disorders (NORD) – Information and advocacy for rare disease patients.
Website: rarediseases.org

Orphanet – European database of rare diseases and support resources.
Website: orpha.net

EURORDIS – European alliance of rare disease patient organizations.
Website: eurordis.org

Leukemia & Lymphoma Society – Support and resources for blood cancer patients.
Website: lls.org

Related conditions

Essential thrombocythemia
Myelofibrosis
Chronic myeloid leukemia
Secondary polycythemia
Mastocytosis

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.